Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

150%

6 of 4 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 3

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 2(3)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01048593Phase 2Terminated

Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

Role: lead

NCT02547623Phase 3Completed

Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery

Role: lead

NCT02006888Phase 3Completed

The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

Role: lead

NCT01175395Phase 1Completed

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)

Role: collaborator

NCT01606735Phase 2Completed

Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

Role: lead

NCT01214174Phase 2Terminated

Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

Role: lead

All 6 trials loaded